Vermillion Completes Acquisition of Correlogic Ovarian Cancer Dx Business | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Vermillion today said that it has completed the acquisition of the assets associated with Correlogic Systems' ovarian cancer diagnostics business for $435,000 in cash.

Vermillion said early last month that it had acquired the assets of Correlogic, a firm operating under Chapter 11 bankruptcy protection.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."